Table 3 Evaluation of the preliminary outcomes of the program for patients who received hormone therapy.
Outcome | MIG (n = 36)a | CG (n = 40)a | Cohen’s db | Generalized estimating equationc | ||||
---|---|---|---|---|---|---|---|---|
Time | Group × time interaction effects | |||||||
Mean | SD | Mean | SD | B (SE) | B (SE) | 95% CI | ||
Primary outcomes | ||||||||
Positive thinking | ||||||||
Pre-test | 67.17 | 7.07 | 67.23 | 7.42 | < − 0.01 | |||
8 weeks | 68.83 | 7.43 | 67.13 | 8.06 | 0.22 | − 0.10 (0.82) | 1.77 (1.27) | − 0.73, 4.26 |
12 weeks | 68.50 | 8.73 | 66.62 | 7.57 | 0.23 | − 0.28 (0.77) | 1.61 (1.25) | − 0.83, 4.06 |
General QOL | ||||||||
Pre-test | 79.86 | 13.95 | 79.18 | 15.42 | 0.05 | |||
8 weeks | 80.89 | 13.84 | 79.28 | 19.54 | 0.10 | 0.10 (2.01) | 0.93 (2.77) | − 4.50, 6.35 |
12 weeks | 80.44 | 14.63 | 80.46 | 16.30 | < − 0.01 | 0.66 (1.73) | − 0.07 (2.48) | − 4.93, 4.79 |
Prostate cancer-specific QOL | ||||||||
Pre-test | 116.39 | 18.44 | 115.00 | 20.92 | 0.07 | |||
8 weeks | 118.25 | 17.69 | 116.75 | 25.24 | 0.07 | 1.75 (2.58) | 0.11 (3.53) | -6.81, 7.04 |
12 weeks | 118.19 | 18.57 | 117.35 | 21.92 | 0.04 | 1.39 (2.35) | 0.42 (3.21) | -5.88, 6.71 |
Hormone symptoms and distress | ||||||||
Pre-test | 85.67 | 14.48 | 84.66 | 15.45 | 0.07 | |||
8 weeks | 87.25 | 12.91 | 86.19 | 15.29 | 0.08 | 1.53 (2.34) | 0.04 (2.88) | − 5.61, 5.69 |
12 weeks | 83.40 | 14.71 | 86.79 | 14.55 | − 0.23 | 1.72 (2.21) | − 3.99 (3.18) | − 10.23, 2.24 |
Secondary outcomes | ||||||||
Social support | ||||||||
Pre-test | 34.69 | 8.20 | 35.43 | 9.56 | − 0.08 | |||
8 weeks | 34.89 | 9.04 | 34.33 | 9.38 | 0.06 | − 1.10 (1.00) | 1.29 (1.66) | − 1.95, 4.54 |
12 weeks | 34.44 | 10.00 | 33.49 | 9.15 | 0.01 | − 1.36 (1.50) | 1.11 (2.05) | − 2.90, 5.12 |
Self-efficacy | ||||||||
Pre-test | 29.44 | 5.84 | 29.90 | 5.32 | − 0.08 | |||
8 weeks | 29.08 | 4.00 | 30.18 | 5.16 | − 0.24 | 0.28 (0.65) | − 0.64 (0.97) | − 2.53, 1.26 |
12 weeks | 30.47 | 5.69 | 29.70 | 5.02 | 0.14 | − 0.07 (0.77) | 1.10 (1.20) | − 1.25, 3.44 |